Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).

Stanford L Peng,Pamela L Kunz,Teri A Longacre,Laura Saunders,Eric Jay Small,Jiaoti Huang,Sheila Bheddah,Courtney L Scaife,Lowell Brian Anthony,Rahul Raj Aggarwal,Jill E Shea,Sam Williams,Scott Dylla,Eun Y Lee,Douglas Wilmot Ball,Barry Nelkin,Allison J Zemek

doi:10.1200/jco.2016.34.15_suppl.11611

Metastatic melanoma, glioblastoma and high-grade extrapulmonary neuroendocrine carcinomas (NECs) as novel indications for rovalpituzumab tesirine: A delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC).

Stanford L Peng, Pamela L Kunz + Show 15 more

https://doi.org/10.1200/jco.2016.34.15_suppl.11611

Copy DOI

Journal: Journal of Clinical Oncology	Publication Date: May 20, 2016
Citations: 3

Affiliation: ChemoCentryx (United States), Stanford University, Stanford Medicine, University of California, San Francisco, Duke Medical Center, University of Utah, University of Kentucky, Johns Hopkins University

#Delta-like Protein 3 #Antibody-drug Conjugate + Show 8 more

Abstract
Full-Text
Similar Papers

Abstract

11611Background: DLL3 is highly expressed in tumor-initiating cells (TIC) in small cell lung cancer (SCLC), where the DLL3-targeted ADC rovalpituzumab tesirine (Rova-T; SC16LD6.5) is able to eradic...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal of Clinical Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.